Director of Biomed Consult Ltd, 22 Acacia Road, Swansea SA3 5LF, UK
Received date: September 01, 2013; Accepted date: September 02, 2013; Published date: September 06, 2013
Citation: Donev R (2013) An Introduction to my Research Interests. J Biomol Res Ther 2:e116. doi: 10.4172/2167-7956.1000e116
Copyright: © 2013 Donev R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Journal of Biomolecular Research & Therapeutics
During his PhD thesis Dr. Rossen Donev studied spatial organisation of mitotic and interphase chromosomes and chromatin dynamic throughout the cell cycle with respect to the control of gene expression [1-4]. After obtaining PhD in 1999, he moved to the Imperial Cancer Research Fund in London, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) where Rossen Donev  worked as a Research Fellow in the Human Cytogenetics Laboratory. Here Dr. Donev  continued his work on the control of gene expression focusing on the Major Histocompatibility Complex (HMC) in humans. Donev  developed a novel atomic force microscopy based approach for identifying protein binding sites in nucleic acids. Furthermore, he discovered a mechanism controlling alternative splicing of the Amyloid Precursor Protein (APP) mRNA and secretion of β-amyloid peptide by cultured neurons . In 2003 Dr. Donev moved to the School of Medicine, Cardiff University where he gained extensive experience in innate immunity. In 2007 he was awarded an MRC New Investigator Award to develop his own research laboratory. He combined his expertise in molecular cell biology, tumour biology and immunology to develop a new strategy for sensitisation of tumours to immunoclearance [8,9]. This new strategy proved to be highly efficient not only in vitro but also in an animal model of malignant melanoma giving a great promise in stimulating our immune system to fight cancer.
In 2010 Dr. Donev was appointed Lecturer in the Molecular Psychiatry and Psychopharmacology group at the School of Medicine, Swansea University. Here he applied his expertise in molecular biology, gene expression and cancer therapy to the molecular psychiatry and developed his own translational and multidisciplinary research in behavioural biochemistry [10-13]. In 2012 Dr. Donev founded his company specialised in scientific publishing and consultancy services. He has consulted on a number of topics related to signalling/molecular mechanisms underlying biochemical alterations in neurodevelopmental disorders and identification of suitable targets for drug development.
Dr. Donev’s innovative and interdisciplinary research has been internationally recognised resulting in his appointment in 2010 as Editor-in-Chief of the Elsevier’s ‘Advances in Protein Chemistry and Structural Biology’ and Editorial Board Member of several other journals. He has chaired scientific sessions at 13th and 14th World Congresses on Advances in Oncology in Greece and gave two plenary talks at an international workshop on adult ADHD-Translating Research into Practice in Clij-Napoca, Romania.